Pediatric Nephrology

, Volume 30, Issue 10, pp 1879–1888 | Cite as

Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis

  • Kevin J. Downes
  • Neha R. Patil
  • Marepalli B. Rao
  • Rajesh Koralkar
  • William T. Harris
  • John P. Clancy
  • Stuart L. Goldstein
  • David J. AskenaziEmail author
Original Article



Aminoglycoside (AG) therapy is a common cause of acute kidney injury (AKI) in cystic fibrosis (CF) patients. The aim of this study was to identify factors associated with AKI during intravenous AG courses in this population.


This was a matched case–control study utilizing two independent cohorts of hospitalized CF patients receiving ≥3 days of intravenous AG at Cincinnati Children’s Hospital Medical Center and Children’s of Alabama. All admissions with AKI (cases, N = 82) were matched to two randomly selected admissions without AKI (controls, N = 164) by center, gender, and age ±3 years of the case. AKI was defined as a 1.5-fold increase in the baseline serum creatinine (SCr) level or by an increase in SCr level of 0.3 mg/dL within 48 h. Admissions with AKI before day 4 or without at least weekly SCr monitoring were excluded from the analysis. Factors were compared between cases and controls using simple and multiple conditional logistic regression.


Multivariable analysis identified receipt of an AG within 90 days prior to admission, longer duration of AG therapy, low serum albumin, and receipt of trimethoprim/sulfamethoxazole as independent risk factors for developing AKI. Infection with Staphylococcus aureus diminished the odds of developing AKI.


This study identifies risk factors contributing to AG-associated AKI in CF patients. These findings can be used to anticipate high-risk scenarios and limit AKI in CF patients under clinical care.


Acute renal failure Adverse drug events Antibiotics Drug-induced nephrotoxicity Pediatrics 


Sources of funding

There was no direct funding for this study. Dr. Downes was supported by the National Institute of Child Health and Human Development of the National Institutes of Health under award number 5T32HD069054, Cincinnati Training Program in Pediatric Clinical and Developmental Pharmacology. Dr. Harris receives funding from the Cystic Fibrosis Foundation (HARRIS12Q0). Dr. Clancy receives grant support from the NIH (NHLBI-FOA-HL 12–035) and the Cystic Fibrosis Foundation (R457-CR11, AMIN09YO). Dr. Goldstein is supported in part by the Agency for Healthcare Research and Quality Center for Education and Research on Therapeutics grant (AHRQ CERT 1U19HS021114). Dr. Askenazi receives funding from the Pediatric and Infant Center for Acute Nephrology (PICAN) which is sponsored by Children’s of Alabama and the University of Alabama at Birmingham’s School of Medicine, Department of Pediatrics and Center for Clinical and Translational Science (CCTS). Funding for REDCap at CCHMC is provided by Center for Clinical and Translational Science and Training grant support (UL1-RR026314). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest



  1. 1.
    Rougier F, Claude D, Maurin M, Maire P (2004) Aminoglycoside nephrotoxicity. Curr Drug Targets Infect Disord 4:153–162CrossRefPubMedGoogle Scholar
  2. 2.
    Zappitelli M, Moffett BS, Hyder A, Goldstein SL (2011) Acute kidney injury in non-critically ill children treated with aminoglycoside antibiotics in a tertiary healthcare centre: a retrospective cohort study. Nephrol Dial Transplant 26:144–150CrossRefPubMedGoogle Scholar
  3. 3.
    Askenazi DJ, Feig DI, Graham NM, Hui-Stickle S, Goldstein SL (2006) 3–5 year longitudinal follow-up of pediatric patients after acute renal failure. Kidney Int 69:184–189CrossRefPubMedGoogle Scholar
  4. 4.
    Abitbol CL, Bauer CR, Montane B, Chandar J, Duara S, Zilleruelo G (2003) Long-term follow-up of extremely low birth weight infants with neonatal renal failure. Pediatr Nephrol 18:887–893CrossRefPubMedGoogle Scholar
  5. 5.
    Coca SG, Singanamala S, Parikh CR (2012) Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81:442–448PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Wehbe E, Brock R, Budev M, Xu M, Demirjian S, Schreiber MJ, Stephany B (2012) Short-term and long-term outcomes of acute kidney injury after lung transplantation. J Heart Lung Transplant 31:244–251CrossRefPubMedGoogle Scholar
  7. 7.
    Moffett BS, Goldstein SL (2011) Acute kidney injury and increasing nephrotoxic-medication exposure in noncritically-ill children. Clin J Am Soc Nephrol 6:856–863PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Menon S, Kirkendall ES, Nguyen H, Goldstein SL (2014) Acute kidney injury associated with high nephrotoxic medication exposure leads to chronic kidney disease after 6 months. J Pediatr 165:522–527, e522CrossRefPubMedGoogle Scholar
  9. 9.
    Contreras AM, Ramirez M, Cueva L, Alvarez S, de Loza R, Gamba G (1994) Low serum albumin and the increased risk of amikacin nephrotoxicity. Rev Invest Clin 46:37–43PubMedGoogle Scholar
  10. 10.
    Cortes J, Gamba G, Contreras A, Pena JC (1990) Amikacin nephrotoxicity in patients with chronic liver disease. Rev Invest Clin 42:93–98PubMedGoogle Scholar
  11. 11.
    Gamba G, Contreras AM, Cortes J, Nares F, Santiago Y, Espinosa A, Bobadilla J, Jimenez Sanchez G, Lopez G, Valadez A (1990) Hypoalbuminemia as a risk factor for amikacin nephrotoxicity. Rev Invest Clin 42:204–209PubMedGoogle Scholar
  12. 12.
    Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P (1993) Once versus thrice daily gentamicin in patients with serious infections. Lancet 341:335–339CrossRefPubMedGoogle Scholar
  13. 13.
    Rougier F, Ducher M, Maurin M, Corvaisier S, Claude D, Jelliffe R, Maire P (2003) Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet 42:493–500CrossRefPubMedGoogle Scholar
  14. 14.
    Prins JM, Weverling GJ, de Blok K, van Ketel RJ, Speelman P (1996) Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy. Antimicrob Agents Chemother 40:2494–2499PubMedCentralPubMedGoogle Scholar
  15. 15.
    Leehey DJ, Braun BI, Tholl DA, Chung LS, Gross CA, Roback JA, Lentino JR (1993) Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. J Am Soc Nephrol 4:81–90PubMedGoogle Scholar
  16. 16.
    Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN (1993) Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 167:173–179CrossRefPubMedGoogle Scholar
  17. 17.
    Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM (1990) Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 10:378–382PubMedGoogle Scholar
  18. 18.
    Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL (1999) Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 43:1549–1555PubMedCentralPubMedGoogle Scholar
  19. 19.
    Oliveira JF, Silva CA, Barbieri CD, Oliveira GM, Zanetta DM, Burdmann EA (2009) Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother 53:2887–2891PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Gerlach AT, Stawicki SP, Cook CH, Murphy C (2011) Risk factors for aminoglycoside-associated nephrotoxicity in surgical intensive care unit patients. Int J Crit Illn Inj Sci 1:17–21PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Al-Aloul M, Miller H, Stockton P, Ledson MJ, Walshaw MJ (2005) Acute renal failure in CF patients chronically infected by the Liverpool epidemic Pseudomonas aeruginosa strain (LES). J Cyst Fibros 4:197–201CrossRefPubMedGoogle Scholar
  22. 22.
    Bertenshaw C, Watson AR, Lewis S, Smyth A (2007) Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 62:541–545PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A (2008) Case–control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 63:532–535CrossRefPubMedGoogle Scholar
  24. 24.
    Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ (2005) Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 39:15–20CrossRefPubMedGoogle Scholar
  25. 25.
    Hmiel SP, Beck AM, de la Morena MT, Sweet S (2005) Progressive chronic kidney disease after pediatric lung transplantation. Am J Transplant 5:1739–1747CrossRefPubMedGoogle Scholar
  26. 26.
    Kellum JA (2012) KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2:19–36CrossRefGoogle Scholar
  27. 27.
    Elin RJ (2011) Appendix: Reference intervals and laboratory values. In: Goldman L, Schafer AI (eds) Goldman’s Cecil medicine, 24th edn. Saunders Elsevier, Philadelphia, pp 2558–2569Google Scholar
  28. 28.
    Arcara KM (2012) Blood chemistries and body fluids. In: Johns Hopkins Hospital, Arcara KM, Tschudy M (eds) The Harriet Lane handbook, 19th edn. Elsevier/Mosby, Philadelphia, pp 639–650Google Scholar
  29. 29.
    McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B (2009) Worldwide prevalence of anaemia, WHO vitamin and mineral nutrition information system, 1993–2005. Public Health Nutr 12:444–454CrossRefPubMedGoogle Scholar
  30. 30.
    Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL (2002) 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11:1–190Google Scholar
  31. 31.
    Lexicomp® (2009) Drug information handbook. Lexi-Comp, Inc., HudsonGoogle Scholar
  32. 32.
    Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:377–381PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Kaseda R, Hosojima M, Sato H, Saito A (2011) Role of megalin and cubilin in the metabolism of vitamin D(3). Ther Apher Dial 15(Suppl 1):14–17CrossRefPubMedGoogle Scholar
  36. 36.
    Watanabe A, Nagai J, Adachi Y, Katsube T, Kitahara Y, Murakami T, Takano M (2004) Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J Control Release 95:423–433CrossRefPubMedGoogle Scholar
  37. 37.
    Maki DG, Fox BC, Kuntz J, Sollinger HW, Belzer FO (1992) A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine. J Lab Clin Med 119:11–24PubMedGoogle Scholar
  38. 38.
    Fraser TN, Avellaneda AA, Graviss EA, Musher DM (2012) Acute kidney injury associated with trimethoprim/sulfamethoxazole. J Antimicrob Chemother 67:1271–1277CrossRefPubMedGoogle Scholar
  39. 39.
    de Araujo M, Seguro AC (2002) Trimethoprim-sulfamethoxazole (TMP/SMX) potentiates indinavir nephrotoxicity. Antivir Ther 7:181–184PubMedGoogle Scholar
  40. 40.
    Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, Prof Knox A (2005) Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis–the TOPIC study: a randomised controlled trial. Lancet 365:573–578CrossRefPubMedGoogle Scholar

Copyright information

© IPNA 2015

Authors and Affiliations

  • Kevin J. Downes
    • 1
    • 9
  • Neha R. Patil
    • 6
  • Marepalli B. Rao
    • 4
  • Rajesh Koralkar
    • 6
  • William T. Harris
    • 7
  • John P. Clancy
    • 3
    • 5
  • Stuart L. Goldstein
    • 2
    • 5
  • David J. Askenazi
    • 6
    • 8
    Email author
  1. 1.Division of Infectious DiseasesCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  2. 2.Division of Nephrology and HypertensionCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  3. 3.Division of PulmonologyCincinnati Children’s Hospital Medical CenterCincinnatiUSA
  4. 4.Biostatistics and EpidemiologyUniversity of CincinnatiCincinnatiUSA
  5. 5.College of MedicineUniversity of CincinnatiCincinnatiUSA
  6. 6.Division of NephrologyUniversity of Alabama at BirminghamBirminghamUSA
  7. 7.Division of PulmonologyChildren’s of AlabamaBirminghamUSA
  8. 8.Pediatric and Infant Center for Acute Nephrology (PICAN), Division of NephrologyChildren’s of AlabamaBirminghamUSA
  9. 9.Division of Infectious DiseasesThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations